Impact of Graft Tunnel Placement on Short-Term Clinical Outcome Following Anterior Cruciate Ligament Reconstruction

移植隧道位置对前交叉韧带重建术后短期临床疗效的影响

阅读:1

Abstract

INTRODUCTION: Anterior cruciate ligament (ACL) tears are a common musculoskeletal injury often requiring anterior cruciate ligament reconstruction (ACLR). Many factors are thought to influence patient outcome and determining the extent can allow for optimisation of patient care. One of these factors is graft tunnel placement, both femoral and tibial. The aim of this study was to investigate whether graft tunnel placement influences clinical outcome following ACLR. MATERIALS AND METHODS: The patient responses from six patient-reported outcome measures (PROM) at initial presentation and one year following ACLR, as well as demographic data at presentation, were collected. Graft tunnel placement was evaluated using 10 validated radiological measurements on antero-posterior and lateral radiographs following surgery. RESULTS: A total of 45 patients were included in the study. There was a significant longitudinal improvement (p<0.001) for almost all PROM scores when comparing pre-operative to post-operative results. Overall, no significant correlation was demonstrated between graft tunnel placement and PROM scores, except for a weak association between femoral tunnel positioning on lateral view radiographs and the overall Knee injury and Osteoarthritis Outcome Score (rho=0.37, p=0.038) and the Lysholm score (rho=0.36, p=0.034) and also tibial tunnel placement on lateral view radiographs and the EQ-5D VAS score (rho=0.37, p=0.037). CONCLUSION: ACLR is a clinically successful treatment strategy for patients with symptomatic ACL tears. Graft tunnel positioning does not generally affect clinical outcomes, although there may be a weak association with femoral tunnel positioning on lateral radiographs.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。